Literature DB >> 12196526

The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras.

Concepcion Jimenez1, Carmen Hernandez, Belen Pimentel, Ana C Carrera.   

Abstract

Class IA phosphoinositide 3-kinase (PI3K) is a heterodimer composed of a p85 regulatory and a p110 catalytic subunit that regulates a variety of cell responses, including cell division and survival. PI3K is activated following Tyr kinase stimulation and by Ras. We found that the C-terminal region of p85, including the C-Src homology 2 (C-SH2) domain and part of the inter-SH2 region, protects the p110 catalytic subunit from Ras-induced activation. Although the p110 activity associated with a C-terminal p85 deletion mutant increased significantly in the presence of an active form of Ras, purified wild type p85-p110 was only slightly stimulated by active Ras. Nonetheless, incubation of purified p85-p110 with Tyr-phosphorylated peptides, which mimic the activated platelet-derived growth factor receptor, restored Ras-induced p85-p110 activation. In conclusion, p85 inhibits p110 activation by Ras; this blockage is released by Tyr kinase stimulation, showing that the classical mechanism of class IA PI3K stimulation mediated by Tyr kinases also regulates Ras-induced PI3K activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196526     DOI: 10.1074/jbc.M205893200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling.

Authors:  Zheng Fu; Eliah Aronoff-Spencer; Jonathan M Backer; Gary J Gerfen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 2.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 3.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

4.  Flavonoids in modulation of cell survival signalling pathways.

Authors:  Mohammad Lukman Mansuri; Priyanka Parihar; Isha Solanki; Mordhwaj S Parihar
Journal:  Genes Nutr       Date:  2014-03-30       Impact factor: 5.523

5.  Vasopressin-induced stimulation of the Na(+)-activated K(+) channels is responsible for maintaining the basolateral K(+) conductance of the thick ascending limb (TAL) in EAST/SeSAME syndrome.

Authors:  Lili Fan; Xiaoyan Wang; Dandan Zhang; Xinpeng Duan; Chunlei Zhao; Mingxue Zu; Xinxin Meng; Chengbiao Zhang; Xiao-Tong Su; Ming-Xiao Wang; Wen-Hui Wang; Ruimin Gu
Journal:  Biochim Biophys Acta       Date:  2015-08-28

6.  Quantitative model of Ras-phosphoinositide 3-kinase signalling cross-talk based on co-operative molecular assembly.

Authors:  Harjeet Kaur; Chang Shin Park; Jodee M Lewis; Jason M Haugh
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

7.  Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry.

Authors:  Amit Kumar; Miriam Marqués; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2006-10-02       Impact factor: 4.272

Review 8.  Phosphoinositide 3-kinase controls early and late events in mammalian cell division.

Authors:  Zaira García; Amit Kumar; Miriam Marqués; Isabel Cortés; Ana C Carrera
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

9.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.